RNA insider filings
Atrium Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-09-22. Screen RNA transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 8 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Boyce Sarah — Director | 1 | — | — | 1 |
| Flanagan W. Michael — Director | 1 | — | — | 1 |
| Gallagher Kathleen P. — See Remarks, Director | 1 | — | — | 1 |
| Hoyos Rocio Martin — Chief Strategy Officer | 1 | — | — | 1 |
| Hughes Steven George — Chief Medical Officer | 1 | — | — | 1 |
| Kenney Stephanie — See Remarks | 1 | — | — | 1 |
| Winslow Brendan R. — Chief Financial Officer | 1 | — | — | 1 |
| Younis Husam — Chief Scientific Officer | 1 | — | — | 1 |
Recent insider filings — Atrium Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-22 | 4 | Hoyos Rocio Martin — Chief Strategy Officer | Tax withholding (F): 8,320 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Winslow Brendan R. — Chief Financial Officer | Tax withholding (F): 6,742 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Gallagher Kathleen P. — See Remarks, Director | Tax withholding (F): 11,632 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Kenney Stephanie — See Remarks | Tax withholding (F): 2,375 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Boyce Sarah — Director | Tax withholding (F): 126,418 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Flanagan W. Michael — Director | Tax withholding (F): 22,812 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Hughes Steven George — Chief Medical Officer | Tax withholding (F): 21,459 @ $8.95 | EDGAR |
| 2026-09-22 | 4 | Younis Husam — Chief Scientific Officer | Tax withholding (F): 11,216 @ $8.95 | EDGAR |
| 2026-04-22 | 4 | Kenney Stephanie — See Remarks | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Winslow Brendan R. — Chief Financial Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Hoyos Rocio Martin — Chief Strategy Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Younis Husam — Chief Scientific Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Gallagher Kathleen P. — See Remarks, Director | Grant/award (A): 102,500 @ $0 · Grant/award (A): 205,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | Hughes Steven George — Chief Medical Officer | Grant/award (A): 30,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Skerjanec Simona — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Flanagan W. Michael — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Boyce Sarah — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | WILSON TROY EDWARD — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | BOESS CARSTEN — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Hughes Steven George — Chief Medical Officer | Sale (S): 2,017 @ $72.45 · Sale (S): 2,878 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | Boyce Sarah — President and CEO, Director | Sale (S): 6,394 @ $72.45 · Sale (S): 7,993 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | Flanagan W. Michael — Chief Scientific Officer | Sale (S): 3,976 @ $72.45 · Sale (S): 2,558 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | McCarthy Teresa — Chief Human Resources Officer | Sale (S): 1,476 @ $72.45 · Sale (S): 1,453 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | MacLean Michael F — Chief Financial Officer | Sale (S): 1,807 @ $72.45 · Sale (S): 2,735 @ $72.45 | EDGAR |
| 2026-01-23 | 4 | LEVIN ARTHUR A — Director | Sale (S): 1,758 @ $72.45 | EDGAR |
| 2026-01-09 | 4 | Boyce Sarah — President and CEO, Director | Sale (S): 8,576 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Calderaro Charles III — Chief Technical Officer | Sale (S): 3,727 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | McCarthy Teresa — Chief Human Resources Officer | Sale (S): 1,965 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Hughes Steven George — Chief Medical Officer | Sale (S): 2,373 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Flanagan W. Michael — Chief Scientific Officer | Sale (S): 2,373 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | Moriarty John B — Chief Legal Officer | Sale (S): 2,374 @ $72.23 | EDGAR |
| 2026-01-09 | 4 | MacLean Michael F — Chief Financial Officer | Sale (S): 1,974 @ $72.23 | EDGAR |
| 2025-12-22 | 4 | LEVIN ARTHUR A — Director | Gift (G): 1,330 @ $0 | EDGAR |
| 2025-12-19 | 4 | Calderaro Charles III — Chief Technical Officer | Grant/award (A): 23,250 @ $0 · Tax withholding (F): 9,726 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Flanagan W. Michael — Chief Scientific Officer | Grant/award (A): 27,500 @ $0 · Tax withholding (F): 13,695 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Mosbrooker Eric — Chief Commercial Officer | Grant/award (A): 72,000 @ $0 · Tax withholding (F): 36,564 @ $71.87 · Tax withholding (F): 11,426 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Boyce Sarah — President and CEO, Director | Grant/award (A): 31,000 @ $0 · Tax withholding (F): 15,742 @ $71.87 · Gift (G): 29,159 @ $0 | EDGAR |
| 2025-12-19 | 4 | Gallagher Kathleen P. — Chief Program Officer | Grant/award (A): 72,000 @ $0 · Tax withholding (F): 33,336 @ $71.87 · Tax withholding (F): 8,030 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | McCarthy Teresa — Chief Human Resources Officer | Grant/award (A): 39,000 @ $0 · Tax withholding (F): 17,298 @ $71.87 | EDGAR |
| 2025-12-19 | 4 | Moriarty John B — Chief Legal Officer | Grant/award (A): 56,000 @ $0 · Tax withholding (F): 26,824 @ $71.87 | EDGAR |
| 2025-10-24 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 2,209 @ $10.16 · Sale (S): 2,209 @ $47.54 · Option exercise (M): 2,209 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | McCarthy Teresa — Chief Human Resources Officer | Option exercise (M): 20,000 @ $22.34 · Sale (S): 20,000 @ $50.15 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | Mosbrooker Eric — Chief Commercial Officer | Option exercise (M): 6,562 @ $9.05 · Sale (S): 6,562 @ $45.38 · Option exercise (M): 6,562 (derivative) @ $0 | EDGAR |
| 2025-09-23 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 2,208 @ $10.16 · Sale (S): 2,208 @ $40.58 · Option exercise (M): 2,208 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | McCarthy Teresa — Chief Human Resources Officer | Option exercise (M): 15,000 @ $22.34 · Sale (S): 15,000 @ $41.41 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-09-17 | 4 | Hughes Steven George — Chief Medical Officer | Option exercise (M): 1,542 @ $6.57 · Sale (S): 1,542 @ $45.41 · Option exercise (M): 1,542 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Flanagan W. Michael — Chief Scientific Officer | Option exercise (M): 20,000 @ $14.22 · Sale (S): 20,000 @ $38.94 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-09-09 | 4 | WILSON TROY EDWARD — Director | Option exercise (M): 14,500 @ $12.48 · Sale (S): 14,500 @ $50 · Sale (S): 15,000 @ $50 · Option exercise (M): 14,500 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Boyce Sarah — President and CEO, Director | Option exercise (M): 50,000 @ $1.24 · Sale (S): 50,000 @ $49.95 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-09-05 | 4 | Mosbrooker Eric — Chief Commercial Officer | Option exercise (M): 6,563 @ $9.05 · Sale (S): 6,563 @ $47.07 · Option exercise (M): 6,563 (derivative) @ $0 | EDGAR |
Recent 8-K events — Atrium Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-02 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K/A | 8.01 — Other Events | EDGAR |
| 2026-10-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=RNA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs